Skip to main content
IRIX
NASDAQ Industrial Applications And Services

IRIDEX Reports Higher Q1 Loss Than News, Faces Major Liquidity Challenge with $27.3M Commitments vs. $4.6M Cash

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$1.1
Mkt Cap
$18.265M
52W Low
$0.869
52W High
$1.648
52W Position info
27% above low
Off High info
33% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

IRIX sits 27% above its 52-week low of $0.869.

Summary

IRIDEX reported Q1 2026 results with a higher net loss than anticipated by recent news, alongside declining cash and substantial short-term purchase commitments that pose a significant liquidity risk.


Key Events · Earnings and Guidance · IRIX

  • Net Loss Higher Than News Report

    The company reported a net loss of $0.524 million for Q1 2026, which is significantly higher than the $0.05 million net loss reported in recent news.

  • Declining Cash and Increased Operating Cash Burn

    Cash and cash equivalents decreased by $1.433 million to $4.595 million in Q1 2026. Net cash used in operating activities increased to $1.335 million, up from $1.149 million in the prior year period.

  • Substantial Short-Term Purchase Commitments

    IRIDEX has $27.3 million in non-cancellable purchase commitments due within the next 12 months. This amount is approximately six times its current cash balance and 150% of its market capitalization.

  • Flat Revenue and Reduced Gross Margin

    Total revenues remained flat at $11.799 million compared to $11.896 million in Q1 2025. Gross profit decreased by 6.2% to $4.741 million, and gross margin declined from 42.5% to 40.2%.


Analysis · IRIX · Industrial Applications And Services

IRIDEX's Q1 2026 results reveal a critical liquidity situation. While the net loss improved year-over-year, the company's cash balance is rapidly depleting due to increased operating cash burn. The most pressing concern is the $27.3 million in non-cancellable purchase commitments due within the next 12 months. This figure is approximately six times the company's current cash of $4.6 million and represents 150% of its market capitalization, raising serious doubts about its ability to meet short-term obligations. Furthermore, the reported net loss of $0.524 million is significantly higher than the $0.05 million net loss previously reported in news, adding to the negative outlook.

At the time of this filing, IRIX was trading at $1.10 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $18.3M. The 52-week trading range was $0.87 to $1.65. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IRIX - Latest Insights

IRIX
Jul 16, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.05
Real-time Price: $0.8305 info
Change: -$0.2195 (-21%) info
Market Cap: $14.456M info
IRIX
Jul 13, 2026, 5:49 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $1.06
Real-time Price: $0.8305 info
Change: -$0.2312 (-22%) info
Market Cap: $14.456M info
IRIX
Jul 08, 2026, 8:44 AM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $1.13
Real-time Price: $0.8305 info
Change: -$0.2995 (-27%) info
Market Cap: $14.456M info
IRIX
May 19, 2026, 4:05 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.04
Real-time Price: $0.8305 info
Change: -$0.2095 (-20%) info
Market Cap: $14.456M info
IRIX
Apr 07, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.38
Real-time Price: $0.8305 info
Change: -$0.5497 (-40%) info
Market Cap: $14.456M info